CTEV vs PGNY

For growth investors, Progyny, Inc.

(PGNY) is the stronger pick with 10. 4% revenue growth year-over-year, versus 3. 7% for Claritev Corporation (CTEV). Progyny, Inc. (PGNY) offers the better valuation at 40. 1x trailing P/E (20. 4x forward), making it the more compelling value choice. Analysts rate Claritev Corporation (CTEV) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Claritev Corporation (CTEV) delivered a total return of +0.

8%, compared to -59. 5% for Progyny, Inc. (PGNY). Over 10 years, the gap is even starker: PGNY returned +63. 6% versus CTEV's +0. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Progyny, Inc.

(PGNY) is the lower-risk stock at 0. 61β versus Claritev Corporation's 2. 26β — meaning CTEV is approximately 269% more volatile than PGNY relative to the S&P 500.

By revenue growth (latest reported year), Progyny, Inc.

(PGNY) is pulling ahead at 10. 4% versus 3. 7% for Claritev Corporation (CTEV). On earnings-per-share growth, the picture is similar: Claritev Corporation grew EPS 83. 0% year-over-year, compared to 14. 0% for Progyny, Inc.. Over a 3-year CAGR, PGNY leads at 17. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Progyny, Inc.

(PGNY) is the more profitable company, earning 4. 5% net margin versus -29. 4% for Claritev Corporation — meaning it keeps 4. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PGNY leads at 6. 6% versus 4. 7% for CTEV. At the gross margin level — before operating expenses — CTEV leads at 27. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CTEV: 33.

4% to $39. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Progyny, Inc.

(PGNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61)). Claritev Corporation (CTEV) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PGNY: +63. 6%, CTEV: +0. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.